Table 3.
Genomic alterations detected in the 15 samples
| ID | Mutations detected by NGS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tumor content (%) | KRAS mutation | Mutant alleles (%) | Mutant alleles normalized for tumor content (%) | HS | GNAS mutation | Mutant alleles (%) | Mutant alleles normalized for tumor content (%) | HS | Other mutations (mutant alleles; normalized for tumor content; HS) | MGMT methylationa | MET Expressionb | MET amplificationc | |
| 1 | 45 | G12C | 12 | 27 | 54 | R201H | 16 | 36 | 72 | No | 300 | No | |
| 2 | 40 | G12D | 26 | 65 | 130 | R201H | 24 | 60 | 120 | Yes | 100 | No | |
| 3 | 30 | WT | – | – | – | WT | – | – | – | No | 60 | No | |
| 4 | 40 | G12D | 12 | 30 | 60 | R201H | 11 | 28 | 56 | No | 80 | 2 % small clusters | |
| 5 | 20 | G13D | 7 | 35 | 70 | WT | – | – | – | TP53 R248 W (20 %;100 %; 200) | No | 250 | >5 signals in < 50 % cells |
| 6 | 10 | G13D | 4 | 40 | 80 | WT | – | – | – | Yes | 180 | No | |
| 7 | 20 | G12D | 9 | 45 | 90 | WT | – | – | – | FGFR3 A257 V (9 %; 45 %; 90) LKB1 P319S (8 %; 40 %; 80) | No | 90 | No |
| 8 | 50 | G12D | 13 | 26 | 52 | R201C | 14 | 28 | 56 | TP53 R273H(23 %; 46 %; 92) HNF1A R278 W (5 %; 10 %; 20) | No | 10 | No |
| 9 | 50 | G12D | 30 | 60 | 120 | R201H | 15 | 30 | 60 | Yes | 140 | No | |
| 10 | 30 | G12 V | 8 | 27 | 54 | R201H | 3 | 10 | 20 | No | 160 | 1 % small clusters | |
| 11 | 20 | G12 V | 18 | 90 | 180 | WT | – | – | – | TP53 C238F (19 %; 95 %; 190) | No | 60 | NO |
| 12 | 10 | G12D | 1 | 10 | 20 | R201H | 6 | 60 | 120 | No | 90 | No | |
| 13 | 35 | G12V | 5 | 14 | 28 | R201H | 10 | 29 | 58 | No | 90 | No | |
| 14 | 80 | G12D | 23 | 29 | 58 | R201H | 24 | 30 | 60 | No | 60 | No | |
| 15 | 30 | G12D | 4 | 13 | 26 | WT | – | – | – | No | 140 | No | |
a MGMT methylation status is assessed by methylation-specific Polymerase chain reaction
b MET expression is assessed by immunohistochemistry and is reported as H-score
c MET amplification status is assessed by in situ hybridization